Status:
RECRUITING
Drug Survival of Target Therapies in Atopic Dermatitis
Lead Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational study with drug to evaluate the drug survival of approved target therapies in atopic dermatitis. Patients affected by moderate-severe atopic dermatitis who will start therapy ...
Detailed Description
Atopic dermatitis (AD) is a chronic, inflammatory skin disease with a prevalence of 10% in adults and 20% in children. It is of primary importance to select the best treatment option as as relapses oc...
Eligibility Criteria
Inclusion
- Age 18 years or older
- Diagnosed with moderate-to-severe atopic dermatitis (EASI\>24)
- Undergoing therapy (retrospective cohort) or undertaking systemic therapy with a biological drug or small molecules
- (for retrospective data) presence of at least one follow-up visit after the start of treatment for which clinical and demographic data were collected at baseline and follow-up visits.
- Signature of informed consent to the study and to the processing of personal data for the research
Exclusion
- Patients under 18 years of age
- Patients who have undergone systemic therapy with a biological drug or small molecules for whom the start date of treatment is not available and/or no clinical-demographic data were collected at baseline and at follow-up visits.
- Absence of informed consent to the study and processing of personal data for research purposes.
Key Trial Info
Start Date :
October 12 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 30 2028
Estimated Enrollment :
1167 Patients enrolled
Trial Details
Trial ID
NCT06882148
Start Date
October 12 2023
End Date
October 30 2028
Last Update
March 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
fondazione policlinico universitario agostino gemelli IRCCS
Rome, Italy, 00168